Angiogenic biomarkers in pregnancy: defining maternal and fetal health
Research output: Contribution to journal › Review › Research › peer-review
Standard
Angiogenic biomarkers in pregnancy : defining maternal and fetal health. / Rasmussen, Lene G; Lykke, Jacob A; Staff, Anne C.
In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 94, No. 8, 08.2015, p. 820-32.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Angiogenic biomarkers in pregnancy
T2 - defining maternal and fetal health
AU - Rasmussen, Lene G
AU - Lykke, Jacob A
AU - Staff, Anne C
N1 - © 2015 Nordic Federation of Societies of Obstetrics and Gynecology.
PY - 2015/8
Y1 - 2015/8
N2 - We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes, and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have, in elderly patients, been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Hence dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs to possibly prevent, delay or reduce cardiovascular disease.
AB - We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes, and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have, in elderly patients, been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Hence dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs to possibly prevent, delay or reduce cardiovascular disease.
KW - Antigens, CD
KW - Biomarkers
KW - Female
KW - Fetal Growth Retardation
KW - Humans
KW - Pre-Eclampsia
KW - Predictive Value of Tests
KW - Pregnancy
KW - Pregnancy Proteins
KW - Receptors, Cell Surface
KW - Vascular Endothelial Growth Factor Receptor-1
U2 - 10.1111/aogs.12629
DO - 10.1111/aogs.12629
M3 - Review
C2 - 25753566
VL - 94
SP - 820
EP - 832
JO - Acta Obstetricia et Gynecologica Scandinavica
JF - Acta Obstetricia et Gynecologica Scandinavica
SN - 0001-6349
IS - 8
ER -
ID: 162372700